Clinical Trials | May 23, 2026
Eli lilly’s retatrutide delivers up to 30% weight loss in phase 3 trial
Clears major obesity endpoints at 80 weeks
Clears major obesity endpoints at 80 weeks
The approval was granted by Agenzia Italiana del Farmaco
More than 450 public and private health technology solutions have integrated with the Ayushman Bharat Digital Mission ecosystem
The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment
Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
The ruling brings closure to a nearly decade-long investigation into hospital operations and healthcare delivery practices
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
This collaboration across the NIPER network- Raebareli, Hajipur, Ahmedabad and Hyderabad is strengthening translational research and opnMe access
Subscribe To Our Newsletter & Stay Updated
